CXCL14 Inhibits Colon Cancer Progression by Modulating Tumor Cell Invasion and Immune Microenvironment
Cells · 2026
DOI: 10.3390/cells15100860 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Yinjie Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China. Hauptthemen laut MEDLINE: Tumor Microenvironment, Colonic Neoplasms, Chemokines, CXC, Disease Progression. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Municipal Government Science Innovation grant.
Abstract (Originalsprache)
CXCL14 is a highly conserved chemokine with potential roles in tumor progression and immune modulation. This study investigates the functional impact of CXCL14 on colon cancer by exploring its effects on tumor cell behavior and the immune microenvironment. We generated stable cell lines overexpressing CXCL14 in mouse MC38 and CT26 cells and human HCT15 colon cancer cells, and used these models to assess tumor growth, invasion, and immune cell infiltration. Our results demonstrate that CXCL14 suppresses colon cancer cell proliferation, migration, and metastasis. In vitro, CXCL14 inhibited the expression of matrix metalloproteinases (MMPs), key regulators of epithelial–mesenchymal transition (EMT), suggesting a role in promoting mesenchymal–epithelial transition (MET). Additionally, in vivo studies using a subcutaneous tumor model showed that CXCL14 not only suppressed tumor growth but also enhanced the infiltration of immune cells, including NK cells, dendritic cells (DCs), and T cells, converting the tumor microenvironment from a “cold” to a “hot” phenotype. RNA sequencing and pathway analyses revealed that CXCL14 regulates the expression of genes associated with angiogenesis, immune response, and cell signaling, particularly through the MAPK pathway. Furthermore, CXCL14’s influence on tumor progression was confirmed in a spleen-to-liver metastasis model, where its overexpression reduced metastatic spread. In conclusion, CXCL14 inhibits colon cancer progression by modulating both tumor cell behavior and the immune landscape, making it a promising candidate for targeted immunotherapy. Our findings highlight CXCL14’s potential to enhance anti-tumor immunity and provide new insights into its therapeutic applications in colon cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China.
- The Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education, Modern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan 030006, China.
- Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, 800 Dongchuan Road, Shanghai 200240, China.
ORCID-Profile: Siyi Wang, Yanjing Wang, Buyong Ma, Jingjing Li
Förderung
- National Natural Science Foundation of China
- Shanghai Municipal Government Science Innovation grant
Zitieren
APA
Zhang, Y., Wang, S., Niu, Y., Wang, Y., Ma, B., & Li, J. (2026). CXCL14 Inhibits Colon Cancer Progression by Modulating Tumor Cell Invasion and Immune Microenvironment. Cells. https://doi.org/10.3390/cells15100860
Vancouver
Zhang Y, Wang S, Niu Y, Wang Y, Ma B, Li J. CXCL14 Inhibits Colon Cancer Progression by Modulating Tumor Cell Invasion and Immune Microenvironment. Cells. 2026. doi:10.3390/cells15100860
BibTeX
@article{Zhang2026,
author = {Zhang, Yinjie and Wang, Siyi and Niu, Yuchen and Wang, Yanjing and Ma, Buyong and Li, Jingjing},
title = {CXCL14 Inhibits Colon Cancer Progression by Modulating Tumor Cell Invasion and Immune Microenvironment},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15100860}
}
EUVIMED